Study Phase 2

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Dose-Response Study to Assess the Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity

Trial Information

Generic NameTopiramateProduct NameTOPAMAX®Therapeutic AreaNutritional and Metabolic DiseasesEnrollment385% Female85.3%% White76.3%
Product ClassAnticonvulsantsSponsor Protocol NumberTOPMAT-OBES-001Data PartnerJohnson & JohnsonCondition StudiedObesityMean/Median Age (Years)44.3

Supporting Documentation

  • Collected Datasets Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.